Contact this trialFirst, we need to learn more about you.
PLK4 Inhibitor
RP-1664 for Solid Tumors
Recruiting1 awardPhase 1
New York, New York
"This trial aims to find a safe and well-tolerated dose of a new drug called RP-1664 that is taken by mouth. The study will also look at how the drug is absorbed and
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.